Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

TransMedics (TMDX) Other financing activities (2019 - 2025)

TransMedics has reported Other financing activities over the past 3 years, most recently at $138000.0 for Q3 2025.

For Q3 2025, Other financing activities changed N/A year-over-year to $138000.0; the TTM value through Sep 2025 reached $723000.0, changed N/A, while the annual FY2020 figure was $705000.0, 85.45% down from the prior year.
Other financing activities for Q3 2025 was $138000.0 at TransMedics, down from $366000.0 in the prior quarter.
Over five years, Other financing activities peaked at $138000.0 in Q3 2025 and troughed at $138000.0 in Q3 2025.